EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue

Gunnar Herlin, Lars Ideström, Lars Lundell, Peter Aspelin, Rimma Axelsson

International Journal of Molecular Imaging · 2011

DOI: 10.1155/2011/279345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Imaging, 2011. Verfasst von Gunnar Herlin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, 141 86 Stockholm, Swed…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to a very high degree in multiple neoplastic diseases. No data exist for esophageal carcinoma.

Purpose

To find out whether esophageal carcinoma could be imaged using somatostatin receptor scintigraphy. Material and Methods . 34 patients with esophageal lesions were prospectively examined by 99m Tc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of 99m Tc-depreotide uptake was performed around the lesion ( T ) and in healthy lung parenchyma ( B ). The relative uptake was calculated as T−B/B . Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic ultrasonography.

Results

21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive 99m Tc-depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U test showed a statistically significant difference () between 99m Tc-depreotide uptake in malignant and benign lesions, for both the 2-hour and the 4-hour measurements.

Conclusion

Scintigraphic examination with 99m Tc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity. Our first results showed high specificity which should be used with caution, as the number of patients was relatively low. Further studies are needed to determine the role of the method.

Autor:innen und Institutionen

  • Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, 141 86 Stockholm, Sweden.

Zitieren

APA

Herlin, G., Ideström, L., Lundell, L., Aspelin, P., & Axelsson, R. (2011). Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue. International Journal of Molecular Imaging. https://doi.org/10.1155/2011/279345

Vancouver

Herlin G, Ideström L, Lundell L, Aspelin P, Axelsson R. Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue. International Journal of Molecular Imaging. 2011. doi:10.1155/2011/279345

BibTeX
@article{Herlin2011,
  author = {Herlin, Gunnar and Ideström, Lars and Lundell, Lars and Aspelin, Peter and Axelsson, Rimma},
  title = {Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue},
  journal = {International Journal of Molecular Imaging},
  year = {2011},
  doi = {10.1155/2011/279345}
}
Kostenlos starten →